Showing all 2 results
Leflunomide Tablets
FreeProduct Composition & Available Portfolio Strengths
We supply Leflunomide across the complete compendial strength matrix, enabling clinicians to manage both rapid initial loading cycles and long-term low-dose maintenance blocks.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Leflunomide USP / BP / IP 10 mg Oral Solid Film-Coated Tablet Low-Dose Maintenance: Calibrated for mild-to-moderate maintenance blocks or patients exhibiting sensitive hepatic profiles. Leflunomide USP / BP / IP 20 mg Oral Solid Film-Coated Tablet The Core Commercial Volume: First-line international standard daily maintenance dose for active Rheumatoid and Psoriatic Arthritis. Leflunomide USP / BP / IP 100 mg Oral High-Mass Solid Tablet Initial Loading Regimen: High-potency format utilized exclusively for the rapid 3-day initial tissue saturation phase. Ondansetron Orally Disintegrating Tablets
FreeProduct Composition & Available Formats
We supply Ondansetron ODT in the two primary compendial configurations required to support initial introductory pediatric dosing up to high-potency surgical and oncological maintenance regimens.
Active Ingredient Monograph Available Strengths Formulation Delivery Matrix Primary Clinical Application Ondansetron Base / Hydrochloride USP / BP / IP 4 mg Fast-Dispersing Hydrophilic Matrix (ODT) Pediatric & General Antiemetic: First-line baseline dosing for acute gastroenteritis, pediatric oncology protocols, and mild post-operative nausea. Ondansetron Base / Hydrochloride USP / BP / IP 8 mg Fast-Dispersing Hydrophilic Matrix (ODT) High-Potency Emetic Control: Advanced strength engineered for highly emetogenic chemotherapy cycles, abdominal radiation protocols, and immediate post-surgical recovery fields.
